NICE to Review Ban on Alzheimer's Drugs After Appeal
The National Institute for Health and Care Excellence has been ordered to reconsider its ban on two Alzheimer's drugs, donanemab and lecanemab, following successful appeals by manufacturers. This offers new hope for NHS access to treatments that delay dis


